CDK9-Cyclin T1 PPI-IN-1

CDK9-Cyclin T1 PPI-IN-1

• CAS Number: 2995336-58-6
• UNSPSC Description: CDK9-Cyclin T1 PPI-IN-1 (Compound B19) is a selective CDK9-Cyclin T1 protein-protein interaction (PPI) inhibitor. CDK9-Cyclin T1 PPI-IN-1 inhibits cell proliferation in TNBC MDA-MB-231 cells (IC50: 0.044 μM), and induces apoptosis. CDK9-Cyclin T1 PPI-IN-1 inhibits CDK9 transcription activity, reduces the phosphorylation of RNA Pol II CTD ser2. CDK9-Cyclin T1 PPI-IN-1 inhibits tumor growth in a TNBC 4T1 mouse model[1].
• Target Antigen: Apoptosis; CDK
• Type: Reference compound
• Related Pathways: Apoptosis;Cell Cycle/DNA Damage
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/cdk9-cyclin-t1-ppi-in-1.html
• Solubility: 10 mM in DMSO
• Smiles: COC1=CC=C(C=C1)C(NC2=CC(C3=CC(N4CCC(CC4)O)=NC=C3)=CC=N2)=O
• Molecular Weight: 404.46
• References & Citations: [1]Gao G, et al. Design, synthesis, and biological evaluation of novel 4,4'-bipyridine derivatives acting as CDK9-Cyclin T1 protein-protein interaction inhibitors against triple-negative breast cancer. Eur J Med Chem. 2023 Oct 6;261:115858.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported